Literature DB >> 3278946

Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology.

J L Waddington1.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3278946     DOI： 10.1016/0306-3623(88)90005-5

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN： 0306-3623


× No keyword cloud information.
  10 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Repeated SKF 38393 and nigrostriatal system neuronal responsiveness: functional down-regulation is followed by up-regulation after withdrawal.

Authors:  M D Kelland; D K Pitts; A S Freeman; L A Chiodo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

4.  Further evidence for two directions of D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502.

Authors:  A M Murray; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Authors:  H Lublin; J Gerlach; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood.

Authors:  J Hietala; T Seppäla; J Lappalainen; E Syvälahti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Affinity of neuroleptics for D1 receptor of human brain striatum.

Authors:  S Kanba; E Suzuki; S Nomura; T Nakaki; G Yagi; M Asai; E Richelson
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

8.  Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor.

Authors:  David L Gray; John A Allen; Scot Mente; Rebecca E O'Connor; George J DeMarco; Ivan Efremov; Patrick Tierney; Dmitri Volfson; Jennifer Davoren; Edward Guilmette; Michelle Salafia; Rouba Kozak; Michael D Ehlers
Journal:  Nat Commun       Date:  2018-02-14       Impact factor: 14.919

9.  Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.

Authors:  U Shivraj Sohur; David L Gray; Sridhar Duvvuri; Yao Zhang; Kathleen Thayer; Gang Feng
Journal:  Neurol Ther       Date:  2018-10-25

10.  PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.

Authors:  Robert Riesenberg; John Werth; Yao Zhang; Sridhar Duvvuri; David Gray
Journal:  Ther Adv Neurol Disord       Date:  2020-03-06       Impact factor: 6.570
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.